BioMarin Pharmaceutical, BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.
Wedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price,
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded to Outperform at Oppenheimer
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat reports.
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates.
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...
BioMarin upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
FierceBiotech3d
As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought
The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...
Oppenheimer upgrades BioMarin on long term outlook
Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...
Oppenheimer upgrades BioMarin with stage set for increasing interest
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Why Is BioMarin Stock Trading Higher On Thursday?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ...
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.
American Association of Individual Investors4d
Which Is a Better Investment, BioMarin Pharmaceutical Inc. or Insmed Incorporated Stock?
Learn more about whether BioMarin Pharmaceutical Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the ...